Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Accounts Payables (2016 - 2025)

Sangamo Therapeutics has reported Accounts Payables over the past 16 years, most recently at $14.4 million for Q4 2025.

  • Quarterly results put Accounts Payables at $14.4 million for Q4 2025, down 6.77% from a year ago — trailing twelve months through Dec 2025 was $14.4 million (down 6.77% YoY), and the annual figure for FY2025 was $14.4 million, down 6.77%.
  • Accounts Payables for Q4 2025 was $14.4 million at Sangamo Therapeutics, down from $15.6 million in the prior quarter.
  • Over the last five years, Accounts Payables for SGMO hit a ceiling of $22.4 million in Q4 2022 and a floor of $8.0 million in Q3 2021.
  • Median Accounts Payables over the past 5 years was $15.4 million (2023), compared with a mean of $14.8 million.
  • Biggest five-year swings in Accounts Payables: tumbled 55.4% in 2021 and later soared 129.72% in 2022.
  • Sangamo Therapeutics' Accounts Payables stood at $9.8 million in 2021, then soared by 129.72% to $22.4 million in 2022, then crashed by 31.93% to $15.3 million in 2023, then increased by 1.48% to $15.5 million in 2024, then fell by 6.77% to $14.4 million in 2025.
  • The last three reported values for Accounts Payables were $14.4 million (Q4 2025), $15.6 million (Q3 2025), and $10.7 million (Q2 2025) per Business Quant data.